SNGX - Soligenix adds 11% FDA nod to start mid-stage trial for psoriasis candidate

Clinical-stage biotech Soligenix (NASDAQ:SNGX) added ~11% in the pre-market Tuesday after the company announced that the FDA cleared its investigational new drug (IND) application to start a mid-stage trial for SGX302, an experimental therapy for psoriasis. The Phase 2a trial designed to evaluate topical version of SGX302 (synthetic hypericin) is on track to begin patient enrollment in 4Q 2022, the company said. The randomized, double-blind, placebo-controlled study is expected to recruit up to 32 adult subjects with mild to moderate, stable psoriasis impacting 2 – 30% of their body. Patients will receive twice weekly placebo or SGX302 for up to 18 weeks. The efficacy endpoints of the study include the degree of lesion clearance and quality of life indices, as reported by patients.

For further details see:

Soligenix adds 11% FDA nod to start mid-stage trial for psoriasis candidate